Abstract
Small-cell lung carcinoma rarely metastasizes to the ovary. Only few cases of this condition have been reported to date. A 42-year-old female nonsmoker was an outpatient after receiving treatment for small-cell lung carcinoma. Approximately 45 months after the first-line treatment, the pro-gastrin-releasing peptide level exhibited a gradual increase. Positron emission tomography-computed tomography revealed abnormal accumulation in the left ovary. Accordingly, we performed laparoscopic salpingo-oophorectomy. Both pathological and immunohistochemical examinations (thyroid transcription factor-1, synaptophysin, and chromogranin A staining) led to the diagnosis of ovarian metastasis of small-cell lung carcinoma. The pro-gastrin-releasing peptide level declined postoperatively, and no recurrence has been reported thus far. Here we reported an extremely rare case of small-cell lung carcinoma metastatic to the ovary after several years of receiving the initial treatment for small-cell lung carcinoma, which, however, exhibited an excellent course postoperatively.
Highlights
Small-cell lung carcinoma (SCLC) is a type of lung cancer characterized by high proliferative ability and metastatic potential
SCLC is a type of lung cancer that is known to recur in various organs of the body, including the brain, liver, lung, and bone
Studies have revealed that SCLC is very aggressive, and metastases to the lymph nodes and distant organs have already been recognized at its diagnosis
Summary
Small-cell lung carcinoma (SCLC) is a type of lung cancer characterized by high proliferative ability and metastatic potential. We present a unique case of a patient with SCLC with ovarian metastasis 4 years after receiving the first-line treatment but exhibited good results with surgical treatment. A bronchoscopic biopsy revealed SCLC (LD: c-T2aN1M0; Stage IIA, Fig. 1a) Her metastatic workup was negative, which comprised cranial magnetic resonance imaging (MRI) and bone scintigraphy. The patient underwent additional chemotherapy with amrubicin alone [45 mg/m2 (day 1, 2, 3), cisplatin + etoposide [80 mg/ m2 cisplatin (day1) + 100 mg/m2 etoposide (day 1, 2, 3)], and carboplatin + irinotecan [AUC5 carboplatin (day1) + 50 mg/ m2 irinotecan (day 1, 8, 15)] Despite this treatment, the ProGRP level did not decrease. These findings were consistent with metastatic SCLC in the ovary. As the ProGRP level markedly decreased, we did not perform any additional treatment. 11 months after this recurrence, her carcinoma has not relapsed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
